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Summary The prognostic value of preoperative serum levels of CA 19-9 and CEA was evaluated in 160
patients with pancreatic cancer. The survival of patients whose tumour marker value was below a certain
cut-off level was compared with the survival of those with a higher value using the log-rank test. The lowest
cut-off level dividing patients into groups with significant difference in survival (P<0.05) was determined by
graphical analysis of chi-square values at different cut-off levels. If stage of disease was not taken into account,
there was a significant difference in survival between patients with low vs high preoperative CA 19-9 and CEA
levels. When patients were classified according to stage, a difference was found for CA 19-9 in stage II-III
patients. Patients with preoperative CA 19-9 below 370 U ml- had a significantly better prognosis than those
with a higher level (P<0.05). In stage I and stage IV patients, no significant difference was found between the
groups at any cut-off level. The analysis of CEA showed a significant difference in survival only in stage IV
patients, with CEA above 15 ng ml-' being associated with shorter survival. In conclusion, in patients with
stage II-III disease, particularly in patients with a non-resectable tumour, in whom the exact spread of the
disease may be difficult to evaluate even at operation, the preoperative CA 19-9 level seems to have a
prognostic value.
The overall prognosis of pancreatic cancer is poor, the 5-year
survival rate being as low as 0.2-3.4% (Gudjonsson, 1987).
Even after surgery for cure the 5-year survival in a meta-
analysis was only 3.4% (Gudjonsson, 1987), although in a
few recent studies higher survival rates have been reported
(Trede et al., 1990; Cameron et al., 1991). The effect of
chemotherapy in different studies has so far been limited.
However, if patients are selected for adjuvant therapy,
knowledge of factors influencing prognosis would be of great
importance. Clinical stage is known to correlate with prog-
nosis (Andren-Sandberg & Ihse, 1983). When comparing
patients with the same stage of pancreatic cancer, very few
prognostic factors are known. Histological type and grade
correlate with prognosis, but in most pancreatic cancers only
cytological specimens are available, and thus the
differentiation grade is difficult to assess reliably.
It has been suggested that tumour markers might be used
for evaluating prognosis in pancreatic cancer, but only a few
studies have been reported. A positive correlation between
low initial levels of CEA and CA 19-9 and survival has been
described (Kalser et al., 1978; Bottger et al., 1990). However,
in these studies stage of the disease was not taken into
account.
The aim of this study was to evaluate the prognostic value
of the preoperative serum levels of CA 19-9 and CEA in
different stages ofpancreatic cancer and to develop a method
of determining the optimal cut-off level for prognostic
evaluation.
Patients and methods
Patients
Serum samples were obtained from 160 patients with histo-
logically or cytologically verified exocrine pancreatic car-
cinoma. Samples were taken preoperatively or at the time of
diagnosis, and were stored at -20°C or -70°C until
analysed. Stage of disease was based on data from clinical
examination, imaging methods, operation records and sur-
gical specimens. For stages I-III, post-operative mortality
was excluded by excluding patients who died within 30 days
from operation. One stage I patient was excluded, leaving 23
patients for analysis, and eight stage 11-111 patients were
excluded and 49 analysed. All stage IV patients were
evaluated, since the mean survival was extremely short and
many patients did not undergo surgery at all. After exclusion
of post-operative mortality, 151 patients were suitable for
analysis. Preoperative CEA values were not available in 13
patients (five stage I patients, two stage II-III patients, six
stage IV patients).
All stage I patients were operated for cure either by pan-
creaticoduodenal resection or total pancreatectomy.
Most of the patients with stage II-III disease underwent a
palliative operation. In these operations local lymph nodes
were not always removed adequately to allow differentiation
between stage II and III. Of our patients, six clearly had
stage II disease and 23 had verified lymph node metastases
(stage III), whereas in 20 patients, local and regional lymph
nodes were not removed for histological analysis. Therefore,
patients with stage II and III disease were combined for
analysis.
Seven stage II-III patients (six stage IT, one stage III)
underwent pancreaticoduodenal resection, 36 patients under-
went palliative procedures, five patients underwent only diag-
nostic laparotomy and one patient was not operated on.
Thirty-five stage IV patients underwent palliative proce-
dures, 12 patients diagnostic laparotomy, one patient diag-
nostic laparoscopy and 31 patients were not operated on.
Stages I-III were also analysed by dividing the patients
into those with resectable and non-resectable disease.
Survival data of the patients were obtained from patient
records, the Finnish Cancer Registry and the Population
Registry.
Assays
The serum concentrations of CA 19-9, defined by mono-
clonal antibody 1116 NS 19-9 against a human colonic
carcinoma cell line (Koprowski et al., 1979), and carcino-
embryonic antigen (CEA), first detected in 1965 (Gold &
Freedman, 1965) and today defined using monoclonal
antibodies, were determined by commercially available CA
19-9 and CEA assays (Centocor, Malvern, USA; Abbott,
Wiesbahn, Germany). The cut-off values recommended by
the manufacturers for diagnostic purposes are 37 U m 'l for
CA 19-9 and 3 ng ml' for CEA.
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Statistical analysis
Analysis was performed using the Microsoft Excel program
for Macintosh computers. Life tables were calculated accord-
ing to Kaplan and Meier (1958). Patients were divided in
groups having a preoperative tumour marker value above or
below a certain cut-off level and their survival was compared.
The statistical significance of the difference in survival of the
groups was calculated using the log-rank test (Peto et al.,
1977). Analyses were made for the whole patient material
and separately for each stage group. Stage groups I-III were
also analysed by dividing patients into those with resectable
(23 stage I patients, six stage II patients and one stage III
patient) and non-resectable disease (42 stage II-III patients).
By gradually increasing the cut-off level, every achieved
marker value was tested as cut-off point, searching for the
lowest tumour marker level that would divide the patients in
groups with a significant difference in survival. Graphs
representing the log-rank chi-square values at the different
cut-off points of CA 19-9 and CEA were created, and the
cut-off values for prognostic evaluation were chosen as the
lowest levels at which the chi-square value reached 3.84,
corresponding to a significance level of P<0.05. This cut-off
value was considered optimal for prognostic evaluation.
Thus, patients with preoperative values above the cut-off
level chosen will belong to a group with significantly worse
prognosis compared with the patients with values below this
level.
Results
Determination ofthe optimal tumour marker cut-offlevelsfor
evaluation ofprognosis
In stage IT-III patients, a significant difference in survival
between patients with marker value below vs above a certain
cut-off level was reached at the preoperative CA 19-9 value
of 370 U ml' (P<0.05). When analysing only stage II-ITT
patients with non-resectable disease the significance was even
higher (P<0.01) (Figure 1). Since no significant difference in
survival was seen for any other subgroup analysed,
370 Uml-I was chosen as cut-off level in all stage groups
when evaluating CA 19-9 as a prognostic factor.
The analysis of CEA showed a significant difference in
survival between patients with a preoperative value below
15 ng ml-' and those with a value above this level. In stages
I-III, the differences in survival were not significant at any
cut-off level. Therefore, .15 ng ml-' was chosen as cut-off
level for prognostic evaluation of CEA in all stage
groups.
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Figure 1 Log-rank chi-square values, corresponding to the
significance of difference in survival between stage II-III (non-
resectable) patients above vs below different cut-off levels of
preoperative serum CA 19-9. The lowest cut-off level at which
chi-square reached a value of 3.84 (dashed line), corresponding to
P<0.05, was 370 U ml-'.
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Figure 2 Life tables for patients with resectable (-) (23 stage I
patients, six stage II patients and one stage III patient), non-
resectable (--) (42 stage 11-III patients) and advanced (---) (79
stage IV patients) pancreatic cancer.
Survival according to stage
In stage I, the median survival was 17.5 months, in stage
II-III 8.6 months (16.3 months in resectable and 7.1 months
in non-resectable disease) and in stage IV 2.3 months. The
corresponding mean survival was 24.7 months, 10.9 months
(17.9 vs 9.8 months) and 4.2 months respectively. The
differences between the survival curves of the stage groups
were highly significant (P<0.001), and the relative death
rates calculated by the log-rank test were 0.42 for stage I,
0.81 for stage II-III and 1.96 for stage IV patients.
Also, dividing stage I-III patients into those with resec-
table and non-resectable disease and comparing these groups
with each other and with stage IV patients, the differences in
survival were highly significant (P<0.001) (Figure 2). The
relative death rates calculated by the log-rank test were 0.42,
0.92 and 1.96 respectively.
CA 19-9
When analysing all patients, there was a significant difference
in survival between those with a preoperative CA 19-9 level
below (69 patients) 370 U ml1 and those whose level was
above (82 patients) 370 U ml' (P<0.01) (Table I).
Table I The median and mean survival times of patients with
pancreatic cancer according to stage and preoperative serum CA
19-9 level
Serum CA 19-9
<370 Uml' >370 Umlt'
Stage I
No. of patients 16 7
Median 18.5 months 17.5 months
Mean 25.6 months 22.8 months
Stage II-III resectable
No. of patients 3 4
Median 16.6 months 14 months
Mean 22 months 14.8 months
Stage 11-III non-resectable
No. of patients 21 21
Median 11.9 months 5.2 months
Mean 13.2 months 6.5 months
Stage IV
No. of patients 29 50
Median 2.7 months 2 months
Mean 4.8 months 3.8 months
All patients
No. of patients 69 82
Median 9.5 months 4.4 months
Mean 12.8 months 6.7 months
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In stage I patients, the median survival was 18.5 months
for patients having a CA 19-9 value lower than 370 Uml1
(16/23 patients), and 17.5 months for those with a higher
value (7/23 patients). The corresponding mean values were
25.6 months and 22.8 months respectively. The difference
between the survival curves was not statistically significant
(P>0.05) (Figure 3; Table I). Nor was there any significant
difference when analysing all patients with resectable disease
(stage I plus stage IH-III resectable).
In stage II-III patients, the median survival for 24
patients with a level lower than 370 U ml-' was 13 months,
compared with 6.4 months for 25 patients with a serum
concentration greater than 370 U ml-'. The difference
between the survival curves was statistically significant
(P<0.05) (Table I).
When excluding stage 11-Ill patients in whom the tumour
was resected, and analysing only patients with non-resectable
disease, the difference between survival curves of patients
with a CA 19-9 level lower vs higher than 370 U ml' was
more significant (P<0.01). The median survival for 21
patients with CA 19-9 below 370 U ml' was 11.9 months
compared with 5.2 months for 21 patients with a serum
concentration greater than 370 Uml-'. The corresponding
mean values were 13.2 months and 6.5 months respectively
(Figure 4; Table I).
In stage IV patients the median survival was 2.7 months
for patients having a value lower than 370 U ml' (29/79
patients) and 2 months for those with a higher value (50/79
patients). The corresponding mean values were 4.8 and 3.8
months respectively. The difference between the survival
curves was not statistically significant (Figure 5; Table I).
CEA
When analysing all patients, there was a significant difference
in survival between those with a preoperative CEA level
below (104 patients) vs above (34 patients) 15 ngml'
(P<0.001).
Only one stage I patient out of 18 had a preoperative CEA
value above 15 ngml-', and this did not allow statistically
meaningful analysis. The same was true when analysing all
patients with resectable disease.
Six out of 47 stage II-III patients had a preoperative CEA
value above 15 ngml-'. All six patients belonged to the
group of patients with non-resectable disease. The difference
in survival between patients with CEA below vs above this
value was not significant.
Of stage IV patients, 27 out of 73 had a CEA value higher
than 15 ngml-' and a median survival of 1 month compared
with 3 months for those with a lower value. The correspond-
ing mean values were 2 and 5 months. The difference was
statistically significant (P<0.01).
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Figure 3 Life tables for stage I patients with pancreatic cancer
with preoperative CA 19-9 lower (-) or higher (---) than
370 U ml-'. There was no significant difference between the
groups.
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Figure 4 Life tables for stage II-Ill patients with non-resectable
pancreatic cancer. Patients with a preoperative CA 19-9 level
lower than 370 Uml-' (-) had significantly better prognosis
than patients with CA 19-9 higher than 370 Uml-' (---).
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Figure 5 Life tables for stage IV patients with pancreatic cancer
with preoperative CA 19-9 lower (-) or higher (---) than
370 Uml-'. There was no significant difference in survival
between the groups.
Combination ofCA 19-9 and CEA
When patients with preoperative CA 19-9 higher than
370 Umlhl and CEA higher than 15 ngml-' were compared
with patients who had marker values below these cut-off
levels, the differences in the survival curves were not
significant in any subgroup analysed. Nor were there
significant differences in any group when comparing patients
who had either CA 19-9 higher than 370 Uml' or CEA
higher than 15 ngml' with those who had lower marker
levels.
Discussion
In pancreatic cancer very few factors that influence prognosis
are known. Stage of disease is known to correlate with
survival, and this was also verified in our study. The
differences in survival between the stage groups were highly
significant. Also, dividing patients into clinically more
relevant groups with resectable (stage I plus stage II-III
resectable), non-resectable (stage II-III) and advanced
disease (stage IV), the differences between the groups were
significant.
Histological type and grade are also known to correlate
with prognosis, but only in some patients is it possible to
obtain adequate histological specimens even at surgery. Most
pancreatic carcinomas are verified cytologically and the
differentiation grade may be difficult to assess reliably from
cytological specimens.
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New prognostic markers would be of great value, and
interest has recently been focused on immunological tumour
markers. In this study, the prognostic value of CA 19-9 and
CEA, two markers commonly used as diagnostic tests for
pancreatic cancer, was evaluated.
Carcinoembryonic antigen (CEA), detected in 1965 by
Gold and Freedman, was for more than a decade the only
tumour marker of any clinical value in the diagnosis of
pancreatic cancer. During the last 10 years it has been
replaced by CA 19-9, which has a clearly higher sensitivity of
72-79% (Klapdor et al., 1984; Haglund et al., 1986;
Steinberg et al., 1986; Benini et al., 1988). CA 19-9 is also
sensitive in detecting recurrences of pancreatic cancer after
operation for cure (Klapdor et al., 1984; Haglund et al.,
1986, 1989). Both markers are also used as diagnostic tests
for other forms of gastrointestinal cancer.
It has been suggested that preoperative levels of tumour
markers could be used for evaluating prognosis, but very few
studies have been published. For both CEA and CA 19-9 a
positive correlation between a low marker level and survival
has been shown (Kalser et al., 1978; Bottger et al., 1990). In
neither study were the survival rates correlated with clinical
stage, which is known to clearly correlate with prognosis. In
this study, we evaluated whether high or low preoperative
CA 19-9 and CEA levels might predict prognosis in patients
of the same stage of pancreatic cancer.
We found it appropriate to exclude patients in stages I-III
who died within 30 days of operation. Also, some other
factors might alter the results, which is why different
subanalyses were performed, as discussed below.
The CA 19-9 antigen corresponds to sialylated Lewisa
blood group substance (Magnani et al., 1982). Therefore, it
has been suggested that individuals lacking the Lewis gene
(Lewisa- b-), i.e. about 5-10% in different populations, are
not able to produce the CA 19-9 antigen (Koprowski et al.,
1982). Thus, the survival data of these patients might distort
the overall results. On the other hand, Masson et al. (1990)
found no difference in CA 19-9 expression between patients
of different Lewis blood groups. Patients with a CA 19-9
level below the detection limit of the test (<6.2 U ml-')
might represent 'non-producers' of the antigen, although we
did not determine the Lewis status of our patients. Excluding
patients with CA 19-9 below 6.2 U ml-' from analysis did
not alter the results of our study.
Elevated values of CA 19-9 and CEA are frequently seen
in benign extrahepatic biliary obstruction, and it has been
suggested that in patients with pancreatic cancer obstruction
of the common bile duct might contribute to the elevation of
serum marker levels (Barkin et al., 1978; Carr-Locke, 1980;
Haglund et al., 1986, 1989; Barone et al., 1988; Paganuzzi et
al., 1988). If the patients of this study had been further
divided into patients with or without jaundice, the groups
would have been too small for meaningful statistical analysis.
However, no clear difference in survival was seen, when
comparing patients presenting with jaundice (serum bilirubin
>201imol 1) with those without jaundice.
For diagnostic purposes, the upper limits of normal, i.e.
the recommended cut-off levels of different markers, were
determined from sera of healthy individuals. This level was
37 U ml-' for the CA 19-9 assay used in this study and
3 ngml-' for the CEA assay. When using these cut-off levels
for prognostic evaluation, no significant differences in sur-
vival were seen within the different stage groups or between
patients with a higher vs lower preoperative marker value.
Since no established cut-off value for prognostic evaluation
was available, we developed a computer program to deter-
mine the lowest cut-off value that divided the patients in two
groups with a significant difference in survival. In stage
II-III patients the optimal cut-off value was almost exactly
370 U ml-', which is tenfold greater than the cut-off level
used for diagnostic purposes. Since no differences in survival
between patient groups were found at any cut-off level in
stages I and IV, the cut-off level of 370 U ml-' was chosen
for further analysis.
Our study confirmed that there is a clear and significant
difference in survival between patients with pancreatic cancer
with a low vs high preoperative tumour marker level, if stage
of disease is not taken into account. However, when patients
were divided according to stage, the differences were
significant only in stage 11-III, both including and excluding
patients with resectable disease, and only for CA 19-9. The
difference in survival may reflect a difference in biological
behaviour between tumours associated with a low level in
contrast to a high level of CA 19-9. On the other hand, the
stage II-111 group is rather non-homogeneous, including
patients with local disease, but with varying degree of spread
to local lymph nodes. The size of the primary tumour may
also vary markedly. Therefore, the difference in survival
between patients with low and high CA 19-9 values might
also reflect differences in tumour burden and spread of
disease.
In stage I patients, the prognosis seemed to be independent
of the preoperative serum expression of CA 19-9 and CEA,
which was also true when analysing all patients with resec-
table disease. This may be explained by the fact that all
patients underwent operation for cure, in which all macro-
scopic tumour tissue was removed. Therefore, post-
operatively they may, from a prognostic point of view, be
considered to be at the same starting point.
In stage IV patients, no difference in survival was seen
between patients with a high or low CA 19-9 level,
independently of the cut-off level chosen. This is probably
explained by the very short overall survival of these patients.
When stage IV patients were divided in two groups according
to the preoperative CEA value, a difference was found in
survival. However, this was true only for patients with ex-
tremely high preoperative values, above 15 ng ml1'. In
clinical practice, this finding is of limited value because of the
very short survival in both groups, 5 months for patients
with a value lower than 15 ngml-' and 2 months for those
with a higher value.
In conclusion, when evaluating prognosis, the preoperative
serum level of CA 19-9 seems to be of some clinical value in
stage II-III patients, in whom spread of disease may be
difficult to assess even at surgery.
One explanation for the limited prognostic value of
preoperative CA 19-9 and CEA levels might be the fact that
the serum level of a tumour marker is not a reflection of the
ability of the tumour tissue to synthesise the antigen, but
rather a consequence of many other factors affecting the
amount ofcirculating antigen. Among these factors are secre-
tion of produced antigen into the bloodstream, metabolism
and excretion of the antigen and occurrence of liver meta-
stases. These factors are difficult to measure and the
mechanisms are partly unknown. Immunohistochemistry
seems a more reliable method of evaluating synthesis of the
antigen, and the correlation between CA 19-9 staining and
prognosis should be studied.
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